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Abstract
Background: Congenital nephrogenic diabetes insipidus (NDI) is characterised by an inability to concentrate
urine despite normal or elevated plasma levels of the antidiuretic hormone arginine vasopressin. We report a
Japanese extended family with NDI caused by an 11.2-kb deletion that includes the entire AVPR2 locus and
approximately half of the Rho GTPase-activating protein 4 (ARHGAP4) locus. ARHGAP4 belongs to the RhoGAP
family, Rho GTPases are critical regulators of many cellular activities, such as motility and proliferation which
enhances intrinsic GTPase activity.
ARHGAP4 is expressed at high levels in hematopoietic cells, and it has been reported that an NDI patient lacking
AVPR2 and all of ARHGAP4 showed immunodeficiency characterised by a marked reduction in the number of
circulating CD3+ cells and almost complete absence of CD8+ cells.
Methods: PCR and sequencing were performed to identify the deleted region in the Japanese NDI patients.
Immunological profiles of the NDI patients were analysed by flow cytometry. We also investigated the gene
expression profiles of peripheral blood mononuclear cells (PBMC) from NDI patients and healthy controls in
microarray technique.
Results: We evaluated subjects (one child and two adults) with 11.2-kb deletion that includes the entire AVPR2
locus and approximately half of the ARHGAP4. Hematologic tests showed a reduction of CD4+ cells in one adult
patient, a reduction in CD8+ cells in the paediatric patient, and a slight reduction in the serum IgG levels in the
adult patients, but none of them showed susceptibility to infection. Gene expression profiling of PBMC lacking
ARHGAP4 revealed that expression of RhoGAP family genes was not influenced greatly by the lack of ARHGAP4.
Conclusion: These results suggest that loss of ARHGAP4 expression is not compensated for by other family
members. ARHGAP4 may play some role in lymphocyte differentiation but partial loss of ARHGAP4 does not
result in clinical immunodeficiency.
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Background
Maintenance of body fluid volume and composition is
essential for proper physiologic function in humans.
Under normal conditions, the glomerular filtration rate of
the two kidneys is 180 L day-1, and up to 90% of the fil-
trate is reabsorbed in the proximal tubule and descending
limb of Henle's loop. The key hormone that regulates rea-
bsorption is the antidiuretic hormone arginine vaso-
pressin (AVP), which is secreted by the posterior pituitary
in response to hypovolemia or hypernatremia [1]. AVP is
transported by the blood to the kidney and binds to
arginine vasopressin receptor 2 (AVPR2), leading to an
increase in intracellular cAMP levels via the stimulatory
Gs protein and adenylate cyclase, and to subsequent acti-
vation of protein kinase A and phosphorylation of
aquaporin 2 (AQP2) water channels [2]. This process is
necessary for proper reabsorption of the water in the prin-
cipal cells of the collecting duct under the control of
AVPR2 [3].
Congenital nephrogenic diabetes insipidus (NDI) is char-
acterised by an inability to concentrate urine despite a
normal or elevated plasma level of AVP. Two genes have
been reported to be associated with NDI; X-linked AVPR2
[4] and autosomal AQP2 [5,6]. The X-linked form of NDI
is present in up to 90% of patients. Males with the disease-
causing mutation are usually affected, and females heter-
ozygous for the disease-causing mutation show various
degrees of penetrance. Skewed X inactivation, which is
preferential methylation of the normal allele of the
AVPR2 gene, can cause NDI in female heterozygotes [7].
To date, 178 AVPR2 mutations, including 12 gross dele-
tions [8-13], have been deposited in the BIOBASE data-
base [14]. Large deletions that lead to complete loss of
AVPR2  and parts of the neighboring genes ARHGAP4
[9,11,15] and L1 cell adhesion molecule (L1CAM) [16] have
been reported. ARHGAP4, which is a member of the
GTPase-activating protein family, is located telomeric to
AVPR2 and is expressed at a high level in hematopoietic
cells. Recently, an NDI patient lacking AVPR2 and all of
ARHGAP4 showed immunodeficiency characterised by a
marked reduction in the number of circulating CD3+ cells
and almost complete absence of CD8+ cells [17]. Herein,
we describe a Japanese extended family with multiple NDI
patients lacking the entire AVPR2  locus and approxi-
mately half of ARHGAP4. Although none of the family
members with NDI showed clinical signs of immunodefi-
ciency, immunologic profiling showed slight abnormali-
ties.
Results
Mutation screening
Two patients (IV-2 and IV-4 in Figure 1) were admitted to
the hospital at the age of 2 months with fever of unknown
origin. NDI was diagnosed on the basis of clinical symp-
toms and laboratory findings (dehydration, hyper-
natremia, and hypotonic urine) and failure to increase
urine osmolarity in response to 1-2esamino-8-D-arginine
vasopressin (dDAVP) (Table 1). The sister (IV-1) had no
history of dehydration, but polyuria and polydipsia were
noticed by her family members, and NDI was diagnosed
on the basis of laboratory findings at the age of 2 years.
None of the patients had any evidence of mental retarda-
tion or significant disease other than NDI. The pedigree of
the Japanese NDI family is shown in Figure 1. Subjects
indicated by a diagonal box (II-1, III-3, III-4, and II-4)
have a history of polyuria and polydipsia since childhood,
but NDI has not been diagnosed.
Genomic DNA from patients and available family mem-
bers was subjected to PCR analysis. We first used the
primer pair (additional file 1) that amplifies the genomic
region between exon 1 and exon 3 of AVPR2, and no PCR
products were amplified from DNA of IV-2 and IV-4 (data
not shown). Therefore, we hypothesised that a large
sequence around the AVPR2 gene was deleted and per-
formed PCR using the primers listed in the additional file
1. After narrowing the deleted region, we designed the
primer pair AVPR2-GAP4 and obtained 386-bp PCR prod-
ucts for III-2, IV-2, III-3, III-4, II-4, III-10, and IV-4 (Figure
1), suggesting that these seven family members carry a
large deletion that covers AVPR2 and part of ARHGAP4.
The AVPR2exon1 and AVPR2exon2 primer pairs amplify
the genomic region of AVPR2 exon 1 and exon 2, respec-
tively. PCR was successful with DNAs from III-2, II-5, III-
9, III-10, and IV-3, indicating that III-2 and III-10 are
asymptomatic female carriers of the deletion. The physical
map and identified deleted regions are shown in Figure 2.
The deleted region includes all of the AVPR2 gene locus
and approximately half of the ARHGAP4 gene. Sequenc-
ing of the 386-bp product from IV-4 revealed that the 5'
and 3' break points were at positions 53,385 and 64,673
bp, respectively, relative to the published sequence (Gen-
Bank U52112.2) with an insertion of the GGGTACAC-
CTC sequence in the break point (Figure 3).
Characteristics of immune function
We evaluated the immune function of 3 family members
lacking ARHGAP4. None of the patients in the present
study had a clinical history of recurrent or opportunistic
infections. Differential leukocyte counts were within nor-
mal range (data not shown), however, a reduction of
CD4+ cells was observed in III-4, and a reduction of CD8+
cells was observed in IV-4 (Table 2). Normal levels of
CD3+CD4+CD45RA+ and CD3+CD4+CD45RO+ T cells
were observed [18] and T cell receptor excision circles
(TREC) of whole blood were within normal range in three
patients tested. Serum IgG levels were relatively low in
adult patients with slight reduction of CD19+ cells in III-BMC Medical Genetics 2008, 9:42 http://www.biomedcentral.com/1471-2350/9/42
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3 and III-4. However differentiation of B cells using IgD,
IgM and CD27 was not different from normal controls
(data not shown).
Microarray analysis
We examined the gene expression profiles of peripheral
blood mononuclear cells (PBMCs) from subjects lacking
ARHGAP4 (III-3 and III-4) and 6 healthy male volunteers
(age, 23–39 years). Transcripts satisfying all of the follow-
ing criteria were identified as up- or down-regulated by
a; The pedigree of the family with NDI Figure 1
a; The pedigree of the family with NDI. A closed pox indicates affected members. Several family members (II-1, II-4, III-3, 
and III-4, indicated by a diagonal box) have histories of polyuria and polydipsia but have not been diagnosed with NDI. Family 
members marked with underlines are ones for PCR analysis. b; PCR amplification of the NDI family members. M, 100 bp 
marker, N, negative control. The regions amplified with the primer pairs (AVPR2exon1, AVPR2exon2, and AVPR2-GAP) are 
shown in Figure 2.
Table 1: basal urine osmolality and plasma osmolality
Basal urine osmolality Urine osmolality response to AVP or dDAVP Plasma osmolality
IV-1 102 102→171 NA
IV-2 30 30→26 NA
IV-4 100 100→125 308
NA; data not availableBMC Medical Genetics 2008, 9:42 http://www.biomedcentral.com/1471-2350/9/42
Page 4 of 9
(page number not for citation purposes)
microarray analysis: (1) transcripts that were expressed in
at least 2 of 8 samples, (2) transcripts that showed statis-
tically significant differences between subjects lacking
ARHGAP4 and, controls (Welch t-test, q < 0.05; multiple
tests were corrected by using the Benjamini and Hochberg
false discovery rate [19]), and (3) transcripts that showed
an average increase/decrease of more than 1.5-fold. Tran-
scripts of ARHGAP4  in PBMCs in III-3 and III-4 were
absent, whereas strong expression was observed in all of
the controls. Up- and down-regulated genes in PBMCs
lacking ARHGAP4 are listed in Table 3. We hypothesized
that lack of ARHGAP4  could be compensated for by
upregulation of other RhoGAP family members. Fifty-
seven transcripts belonging to the RhoGAP family were
included in the microarray analysis, and 25, including
ARHGAP4  were expressed in at least 2 of 8 samples.
Expression levels of the transcripts other than ARHGAP4
are shown in Table 4. None of the transcripts of the
RhoGAP family members were statistically significantly
up/down regulated in the PBMCs.
Discussion
In this study, we identified an extended Japanese family
with X-linked NDI whose affected and carrier members
have an 11.2-kb deletion and 11-bp insertion that leads to
complete loss of the AVPR2  gene and part of the
ARHGAP4 gene.
X-linked congenital NDI is caused by loss of or decreased
function of AVPR2, and large deletions that lead to com-
plete loss of AVPR2 and parts of the neighboring genes
ARHGAP4  and L1CAM [9,11,15] have been
reported.ARHGAP4 is expressed at high levels in hemat-
opoietic cells. Because of the predominant expression pat-
tern in hematopoietic cells, Schoneberg et al [11]
performed immunologic analysis of blood from an NDI
patient with complete loss of the AVPR2 gene and most of
ARHGAP4. They observed a slight reduction in numbers
of CD4+ cells and normal white blood cell counts, prolif-
eration, cytokine and immunoglobulin production, respi-
ratory burst, and phagocytosis. In addition to the patients
in the present study, five NDI patients with partial dele-
tion of ARHGAP4 have been reported [9,11,15], and none
showed clinical signs of immunodeficiency. However,
The physical map and the deleted region in the Japanese NDI family Figure 2
The physical map and the deleted region in the Japanese NDI family. 11,286 bp deletion was observed around AVPR2 
gene. Bold lines indicated amplified regions with primers (AVPR2-GAP, 386 bp with deletion, AVPR2exon1, expected product 
size 583 bp with no deletion, and AVPR2exon2, expected product size 600 bp with no deletion). 5' deleted point occurred 
between LCAP and AVPR2, and 3' deleted point was in the intron 10 of ARHGAP4.BMC Medical Genetics 2008, 9:42 http://www.biomedcentral.com/1471-2350/9/42
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Broides  et al. reported a pediatric NDI patient lacking
AVPR2 and all of ARHGAP4 who showed immunodefi-
ciency characterised by a marked reduction in the number
of circulating CD3+ cells and an almost complete absence
of CD8+ cells [17]. In this patient, the deleted region
included 1.4 kb of intron 1, the first exon of ARHGAP4
and a 2.8 kb sequence between ARHGAP4 and ARD1A;
this sequence is highly conserved across species, and
Broides et al, speculated that this conserved region was the
cause of the immunodeficiency phenotype observed in
their patient. Hematologic tests of our patients showed a
reduction of CD4+ cells in III-4, a reduction of CD8+ cells
in IV-4, and a slight reduction of serum IgG levels in adult
patients, but none of our patients showed susceptibility to
infection. Taken together with the results of previous stud-
ies, our present results suggest that ARHGAP4 plays some
role in lymphocyte differentiation, but does not cause the
immunodeficiency phenotype. ARHGAP4 belongs to the
RhoGAP family which enhances intrinsic GTPase activity.
RhoGTPases are critical regulators of many cellular activi-
ties, such as motility and proliferation. We used the
microarray technique to examine the possible effects on
gene expression patterns in PBMCs by lacking ARHGAP4;
several up-/down- regulated genes were identified. Our
microarray study has several limitations. Firstly, it should
be noted that microarray analysis is a screening method
for detecting genes that may be regulated. Bosotti et al.,
reported that genes detected as differentially expressed by
microarray platforms were also found to be differentially
expressed by real-time quantitative PCR, although differ-
ences in the magnitudes of individual expression ratios
were observed. [20] Secondly, PBMCs comprise a hetero-
geneous population of cells, and the possibility remains
that the gene expression changes observed may merely
reflect changes in the population of cells. However,
because these patients lack ARHGAP4 gene expression in
all tissues and cells, it is likely that gene expression
changes may be detected even in the heterogeneous cell
populations. Gene expression profiling of PBMCs lacking
ARHGAP4 revealed that the expression of RhoGAP family
genes was not influenced greatly by the lack of ARHGAP4,
suggesting that loss of ARHGAP4 expression is not com-
pensated for by other gene family members.
In the present study, one girl (IV-1) was affected by NDI.
Female carriers do not usually show symptoms of NDI as
observed in IV-2 and IV-4, but a small proportion of
female carriers develop varying degrees of polyuria and
polydipsia that can be explained by skewed inactivation
of the X chromosome containing the functional AVPR2
allele. Although genetic testing has not been done for IV-
1, it is very likely that she is a carrier of the deletion and
that skewed X inactivation caused her symptoms.
A recent study showed that ARHGAP4 inhibits the migra-
tion of NIH/3T3 cells and the outgrowth of hippocampal
Sequence of deletion breakpoint in the NDI family Figure 3
Sequence of deletion breakpoint in the NDI family. 5'and 3' breakpoints at positions 53,385 and 64,673 bp, respectively, 
relative to the published sequence (GenBank U52112.2) are indicated with arrows. The sequence is shown in antisense orien-
tation. There is an insertion of the "GAGGTGTACCC" sequence in the break point. Bold lines indicate palindromic sequence 
which could cause the interstitial deletion.BMC Medical Genetics 2008, 9:42 http://www.biomedcentral.com/1471-2350/9/42
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axons and that the N-terminus and C-terminus of
ARHGAP4 play different but essential roles in the potent
inhibition of cell and axon motility [21]. The patients in
the present study lack the C-terminus of ARHGAP4
(amino acids 515–965 according to the reference
sequence NM_001666), but none of them showed clini-
cal signs of immunodeficiencies or neurologic disorders.
Further studies are needed to elucidate the role of
ARHGAP4 in immune function and neuronal develop-
ment.
Table 2: Immunological evaluation of NDI patients
III-3
32 yr
III-4
29 yr
IV-4
5 yr
Normal range (adult) Normal range (children)
CD3+ [%] 74.3 68.9 85.9 55–78 55–83
CD4+/CD3+ [%] 54.9 17.7 69.6 28–57 27–53
CD8+/CD3+ [%] 34.5 61.8 14 10–39 19–34
CD4/CD8 1.6 0.3 5 1.0–3.6 0.9–2.6
CD19+ [%] 5.2 5.7 6.7 6–19 10–31
IgG (mg/dl) 810.0 741.0 754.0 870–1700 600–1450
IgA (mg/dl) 147.0 72.0 105.0 110–410 39–233
IgM (mg/dl) 59.0 127.0 72.0 33–190 69–268
TREC/µgDNA 1.9 × 102 2.8 × 102 1.6 × 103 3.4 ± 3.6 × 102 3.5 ± 2.8 × 103
The normal range of the lymphocyte subpopulation was lower and the upper confidence limit at a confidence level of 0.95. The normal range of IgG, 
IgA, and IgM are calculated as mean - 2SD (lower) and mean + 2SD (upper). The normal range of TREC is expressed as mean ± SD.
Table 3: Up/down regulated genes in PBMC lacking ARHGAP4
Gene Name Description aFold change b q value cAccession
Up-regulation
PLK3 Polo-like kinase 3 4.35 0.0402 NM_004073
NHSL2 NHS-like 2 2.38 0.0453 NM_001013627
PTAFR Platelet-activating factor receptor 2.27 0.0288 NM_000952
KLHL26 Kelch-like 26 1.99 0.0272 NM_018316
MAPKAPK2 Mitogen-activated protein kinase- activated protein kinase 2 1.96 0.0442 NM_032960
CKAP4 Cytoskeleton-associated protein 4 1.85 0.0272 NM_006825
CYB5R3 Cytochrome b5 reductase 3 1.82 0.0328 NM_007326
ZC3H12A Zinc finger CCCH-type containing 1.81 0.0428 NM_025079
FURIN Furin 1.79 0.0448 NM_002569
GRN Granulin 1.76 0.0453 NM 002087
PPOX Protoporphyrinogen oxidase 1.75 0.0307 NM_000309
NQO2 NAD(P)H dehydrogenase, quinone 2 1.74 0.0453 NM_000904
DPH3 Diphthamide biosynthesis protein 3 1.70 0.0307 NM_206831
PGD Phosphogluconate dehydrogenase 1.68 0.00562 NM_002631
RIPK5 Receptor interacting protein kinase 5 1.66 0.0386 NM_015375
CD14 CD14 molecule 1.62 0.0272 NM_000591
PGD Phosphogluconate dehydrogenase 1.57 0.0272 NM_002631
Down-regulation
TUSC4 Tumor suppressor candidate 4 0.63 0.0453 NM_006545
PLEKHG4 Pleckstrin homology domain containing, family G (with RhoGef 0.62 0.0272 NM_015432
SFXN1 Sideroflexin 1 0.61 0.0272 NM_022754
GNRH1 Gonadotropin-releasing hormone 1 0.60 0.0328 NM_000825
PPP1R3E Protein phosphatase 1, regulatory 0.60 0.0383 XM_940069
MC1R Melanocortin 1 receptor 0.56 0.0272 NM_002386
LRCH4 Leucine-rich repeats and calponin homology (CH) domain containing 4 0.55 0.0411 NM_002319
LOC642787 Hypothetical protein LOC642787 0.44 0.0288 XM_926202
SGPP2 Sphingosine-1-phosphate phosphotase 0.09 0.0307 XM_938742
BNIPL BCL2/adenovirus E1B 19 kD 0.06 0.0226 NM_138278
ARHGAP4 Rho GTPase activating protein 4 0.00 0.000567 NM_001666
aThe fold change was determined by calculating the ratio of global normalized signals from the PBMCs of NDI patients to those from the PBMCs of 
normal subjects. bP values corrected by the Benjamini and Hochberg false discovery rate, and expressed as q values cGenBank accession numbersBMC Medical Genetics 2008, 9:42 http://www.biomedcentral.com/1471-2350/9/42
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Conclusion
Our study indicated that loss of ARHGAP4 expression is
not compensated for by other family members. ARHGAP4
may play some role in lymphocyte differentiation but par-
tial loss of ARHGAP4 dose not result in clinical immuno-
deficiency.
Methods
Patients and mutation detection
The pedigree of the Japanese NDI family is shown in Fig-
ure 1. A full verbal and written explanation of the study
was given to family members, and informed consent for
the genetic study was obtained from members who partic-
ipated in this study. Informed consent for the children
was provided by their parents. This study was approved by
the Committee of Ethics of the University of Tsukuba and
was performed in accordance with the ethical standards of
the 1964 Declaration of Helsinki. DNA was extracted
from peripheral blood leukocytes collected in ethylenedi-
aminetetraacetic acid (EDTA). To identify the deleted
region around AVPR2, primers were designed according to
the published sequence (GenBank accession number
U52112.2) with Primer3 software [22]. The primer
sequences are listed in the additional file 1. Sequencing
was performed with the Big Dye Terminator kit (Applied
Biosystems, Foster City, California, USA) on an ABI
PRISM 3100 DNA Sequencer (Applied Biosystems).
Immunological analysis
Peripheral blood samples from III-3, III-4 and IV-4 in Fig-
ure 1 were labeled with monoclonal antibodies according
to the manufacturer's instructions and analysed with a
FACSCalibur system (BD Biosciences, San Jose, Califor-
nia, USA). Monoclonal antibodies were purchased from
BD Biosciences or Beckman-Coulter (Fullerton, Califor-
nia, USA). Quantification of TRECs was performed as
described previously [23]. In brief, total DNA was isolated
from 100 µl of peripheral blood with the use of a QIAamp
DNA Micro Kit (Qiagen, Hilden, Germany) according to
the manufacturer's instructions. The DNA concentration
was determined with a GeneQuant pro system (GE
Healthcare Bio-Sciences Corp. Piscataway, New Jersey,
USA). Quantitative real-time polymerase chain reaction
(PCR) for δRec-ψJα sjTRECs was performed with the fol-
lowing primers and probe: δRec primer, 5'-TCGTGA-
GAACGGTGAATGAAG-3',  ψJα primer, 5'-
CCATGCTGACACC'TCTGGTT-3', and δRec probe, FAM-
5'-CACGGTGATGCATAGGCACCTGC-3'-TAMRA. As an
internal control, RNase P genes were amplified in each
sample tested. In each experiment, serial dilutions (109,
108, 107, 106, 105, 103, 101, and 100) of the subcloned
sjTREC-plasmid (pCR4-TOPO, Invitrogen Corp.,
Carlsbad, California, USA) and RNase P-plasmid were
used as standards for absolute quantification of TRECs
and RNase P copies. Each 20-µl reaction contained 1 µl
Table 4: RhoGAP family gene expressions in PBMC lacking ARHGAP4
Gene Name Description aFold change bq value cAccession
ARHGAP1 Rho GTPase activating protein 1 0.83 0.473 NM_004308
ARHGAP9 Rho GTPase activating protein 9 1.23 0.473 NM_032496
ARHGAP10 Rho GTPase activating protein10 1.01 0.914 NM_024605
ARHGAP12 Rho GTPase activating protein 12 1.03 0.655 NM_018287
ARHGAP17 Rho GTPase activating protein 17 0.67 0.473 NM_018054
ARHGAP19 Rho GTPase activating protein 19 1.16 0.473 NM_032900
ARHGAP21 Rho GTPase activating protein 21 0.98 0.655 NM_020824
ARHGAP24 Rho GTPase activating protein 24 1.33 0.891 NM_001025616
ARHGAP25 Rho GTPase activating protein 25 0.90 0.565 NM_001007231
ARHGAP25 Rho GTPase activating protein 25 0.93 0.83 NM 014882
ARHGAP27 Rho GTPase activating protein 27 0.81 0.473 NM_199282
ARHGAP30 Rho GTPase activating protein 30 1.16 0.473 NM_001025598
ARHGAP30 Rho GTPase activating protein 30 0.86 0.565 NM_181720
BM046 Rho GTPase activating protein 15 0.92 0.655 NM 018460
CDGAP Cdc42 GTPase-activating protein 0.86 0.891 NM 020754
CENTD2 Centaurin, delta 2 1.26 0.473 NM_139181
CENTD3 Centaurin, delta 3 1.12 0.655 NM_022481
GMIP GEM interacting protein 1.17 0.473 NM_016573
MYO9B Myosin IXB 1.20 0.473 NM_004145
OCRL Oculocerebrorenal syndrome of Lowe 1.00 0.655 NM_000276
PIK3R1 Phosphoinositide-3-kinase, regulatory 0.94 0.571 NM_181504
PIK3R2 Phosphoinositide-3-kinase, regulatory subunit 2 (beta) 0.86 0.655 NM_005027
RACGAP1 Rac GTPase activating protein 1 0.83 0.473 NM 013277
RALBP1 RalA binding protein 1 0.84 0.565 NM_006788
aFold change was determined by calculating the ratio of global normalized signals from PBMC of NDI patients to that of normal subjects. bP values 
corrected by the Benjamini and Hochberg false discovery rate, and expressed as q values cGenBank accession numberBMC Medical Genetics 2008, 9:42 http://www.biomedcentral.com/1471-2350/9/42
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DNA, and the final concentration of each component for
TREC-PCR was as follows: 2× TaqMan Universal PCR
Master Mix (Applied Biosystems), 500 nM of each primer,
and 250 nM TaqMan probe. The final concentration of
each component for RNase P-PCR was as follows: 2× Taq-
Man Universal PCR Master Mix and 20× TaqMan RNase P
Primer Probe (VIC dye) Mix (Applied Biosystems). PCR
conditions were 50°C for 2 minutes, 95°C for 10 min-
utes, and 40 cycles at 95°C for 15 seconds and 60°C for 1
minute. Experiments were performed and analysed with
an ABI PRISM 7300 Sequence Detection System (Applied
Biosystems). Results were extrapolated to the number of
TRECs per µg DNA and that of RNase P copies per µg
DNA. To confirm that the DNA yields were adequately
purified, TRECs were also normalised to copies of RNase
P genomic DNA.
Microarray analysis
PBMCs from III-3, III-4, and six healthy male volunteers
(age, 23–39 years) were purified with a Ficoll-Paque™ gra-
dient (GE Healthcare Bio-Sciences Corp.). RNA from
PBMCs was extracted with an RNeasy Mini Kit (Qiagen)
according to the manufacturer's instructions. cRNA was
synthesized with an Illumina®  RNA Amplification Kit
(Ambion, Austin, Texas, USA) according to the manufac-
turer's instructions. In brief, 500 ng total RNA from
PBMCs was reverse transcribed to synthesise first and sec-
ond strand cDNA and purified on spin columns, and in
vitro transcription was performed to synthesise biotin-
labeled cRNA. A total of 1500 ng biotin-labelled cRNA
was hybridised to a Sentrix Human-6 Expression Bead-
Chip version 2 (Illumina, San Diego, California, USA) at
55°C for 18 hours. The hybridised BeadChip was washed
and labelled with streptavidin-Cy3 (GE Healthcare Bio-
Sciences Corp.) and then scanned with the Illumina Bead-
Station 500 System (Illumina). The scanned image was
imported into BeadStudio (Illumina) for analysis. Forty-
eight thousand transcripts representing six whole-genome
samples can be analysed on a single BeadChip. We
included at least two technical replicates (i.e., the same
cRNA samples) for each BeadChip.
Background-corrected values for each probe on the Bead-
Chip array were extracted using BeadStudio version
1.5.1.3 (Illumina). This is based on the average of nega-
tive control genes and is called the method of background
normalization by Illumina. These extracted values were
exported to the software GeneSpring version 7.3.1 (Sili-
con Genetics, Redwood, CA), and per chip and per gene
normalization were performed. The statistical significance
of the microarray data was calculated using the Welch t-
test, and multiple tests were corrected by the Benjamini
and Hochberg false discovery rate [19]. Significance was
defined as q < 0.05.
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